menu

NEWS

Genetika+ Combines PGx, ‘Brain-in-a-Dish’ Model to Personalize Depression Meds

October 11, 2022 | Jessica Kim Cohen – genomeweb NEW YORK – Genetika+ is combining information on patients’ symptoms, pharmacogenetics, and aso-called “brain-in-a-dish” functional testing model in the hopes of improving personalized drugprescribing for psychiatric conditions, with an initial focus on depression.  The Israeli company plans to launch its first drug-matching testing service for major depressivedisorder, dubbed NeuroKaire, next year. Genetika+ hopes to promote NeuroKaire as a service doctorscan use to improve patients’ outcomes on antidepressants, reduce treatment-related side effects, andcut down on trial-and-error prescribing. Millions of people across the globe struggle with major depressive disorder, and prevalence hasincreased with...

READ MORE
Streck Announces Series B Investment in Ceres Nanosciences

La Vista, Nebraska – September 14, 2022 Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres’ Nanotrap® technology platform. “Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers,” said Ceres CEO Ross Dunlap. “We are thrilled to have Streck’s support and guidance in this next, exciting phase of our growth.” This investment builds on the pre-existing partnership between Ceres and Streck,...

READ MORE
KSM Research And Innovation And Genetika+ Partner To Seek AI Solutions For Personalization Of Depression Treatment

Kahn-Sagol-Maccabi (KSM) and Genetika+ form a research partnership to develop and validate AI that personalizes and speeds up an optimal depression treatment TEL AVIV, ISRAEL, August 15, 2022 /EINPresswire.com/ — Kahn-Sagol-Maccabi (KSM), the research and innovation center of Israel’s Maccabi Healthcare Services, and Genetika+, a pioneer in personalized medicine for the brain, are partnering to advance the development of tools to personalize depression treatment using Artificial Intelligence (AI) and advanced analytics. The collaboration between Genetika+ and KSM is focused on conducting large-scale state-of-the-art analysis on extensive data from patients suffering from depression in order to further develop and validate Genetika+’s...

READ MORE
Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market

July 26, 2022 02:00 AM Eastern Daylight Time TEL AVIV, Israel–(BUSINESS WIRE)–Genetika+, a company developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases, announced today an award of up to €17.5 million of grant funding combined with equity investment to bring NeuroKaire to market. This represents the maximum possible grant from the European Commission and will be used for the company’s precision medicine tool for optimizing drug choice to treat major depressive disorder (MDD). The award was granted through the European Commission’s European Innovation Council (EIC) Accelerator for Europe’s high potential start-ups. Genetika+’s proposal was selected from...

READ MORE
Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC

Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic – Results published in Journal of Thoracic Oncology Clinical and Research Reports June 23, 2022 08:00 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology Clinical and Research Reports that demonstrates their blood 5-microRNA signature (miRisk) to predict survival following immunotherapy in advanced non-small cell lung cancer (NSCLC) patients with high PD-L1 expression. “The miRisk score represents an immune focused biomarker that is specifically predictive of response...

READ MORE
Hummingbird Diagnostics Developing miRNA-Based Immunotherapy Predictor on Heels of Positive Study

Apr 07, 2022 | Molika Ashford NEW YORK – New research published last week by scientists from Germany’s Hummingbird Diagnostics and collaborators suggests that blood-borne microRNAs (miRNAs) may enable better personalization of cancer immunotherapy. In the study, appearing in the Nature partner journal Precision Oncology, the investigators used whole-blood miRNA profiling to develop a five-miRNA risk score that is predictive of overall survival in stage IV non-small cell lung cancer patients following immunotherapy — outperforming PD-L1 expression, which is currently the most established biomarker for guiding the use of anti-PD-1 agents. Hummingbird now hopes to commercialize a test based on this biomarker signature to guide immunotherapy in lung...

READ MORE
1 2 3 4 5 9
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER